Clik here to view.
Are small biotechs more productive because they have no other choice?
Over the last few years, much has been written about the poor R&D productivity of the big pharma companies. There is a bit of a controversy as to whether or not small biotechs are truly more...
View ArticleClik here to view.
If the FDA approves the new obesity drugs, will REMS crash the party?
Wow! A lot has happened since my last blog post. Two of the three new obesity drugs up for approval (Qnexa from Vivus and Lorquess from Arena) both received positive responses from their respective...
View ArticleClik here to view.
Vivus’ new obesity drug: Will it get scooped by generics before it even hits...
This past Wednesday, the FDA approved Belviq, the recently renamed obesity drug from Arena. It wasn’t a huge surprise since the FDA review panel gave a strong 18-4 vote of support for its approval....
View ArticleClik here to view.
Just how much profit is there in a new drug?
It seems like the debate over the cost of patented drugs never ends: patients complain about the ever increasing prices and the drug companies complain about the high costs of R&D. However, one...
View ArticleClik here to view.
Big pharma’s “pay-to-delay” deals: Helping or hurting patients?
A few weeks ago it was announced that Jon Leibowitz has decided to leave his post at the Federal Trade Commission. Jon has been the driving force behind the FTC’s attempt to ban so called...
View ArticleClik here to view.
A setback for the hygiene hypothesis
It’s always interesting when a clinical trial you’ve been watching reads out. One of the first posts I wrote for this blog was about a clinical trial that Coronado Biosciences was running based on the...
View ArticleClik here to view.
How the government makes healthcare more expensive by cutting costs
Increasing healthcare costs are one of the most important issues facing the United States today. Although the rate of increase has slowed down over the past few years, the amount of money spent on...
View ArticleClik here to view.
FDA dismisses study that shows generic drugs are lower quality than branded...
In this blog post I’m going to take a step away from the business side of the pharmaceutical industry and dive a little bit deeper in to the science. In March of last year, a paper (paywall) and a...
View ArticleClik here to view.
An unprecedented looked at how biotech prices their drugs
Whether you’re in the biopharma industry or not, you’ve heard about the controversy surrounding the pricing of Sovaldi and Harvoni, two therapies for hepatitis C that have revolutionized the treatment...
View ArticleClik here to view.
If we reduce wastage, drug prices won’t go down
Back in March, the NY Times published an article claiming that we lose $3 billion dollars each year because of the cancer drug that are wasted. The article was inspired by a paper from Memorial Sloan...
View Article
